Home > 약제과 소식 > 최신 의학 정보최신 의학 정보
최신약물정보 (FDA 승인 약물 2013.12-2014.2)
게시일 2014-03-18 09:16
Anoro Ellipta (umeclidinium and vilanterol inhalation powder); GlaxoSmithKline; For the maintenance treatment of chronic obstructive pulmonary disease, Approved December of 2013
Sovaldi (sofosbuvir); Gilead Sciences; For the treatment of hepatitis C, December of 2013
Xiaflex (collagenase clostridium histolyticum); Auxilium; For the treatment of Peyronie's disease, Approved December of 2013
Tretten (Coagulation Factor XIII A-Subunit [Recombinant]); Novo Nordisk; For the treatment of congenital factor XIII (FXIII) A-subunit deficiency, Approved December of 2013
Farxiga (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014
Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014
Northera (droxidopa); Chelsea Therapeutics; For the treatment of neurogenic orthostatic hypotension, Approved February 2014
Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014
Vimizim (elosulfase alfa); BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014
Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014
Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014
Sovaldi (sofosbuvir); Gilead Sciences; For the treatment of hepatitis C, December of 2013
Xiaflex (collagenase clostridium histolyticum); Auxilium; For the treatment of Peyronie's disease, Approved December of 2013
Tretten (Coagulation Factor XIII A-Subunit [Recombinant]); Novo Nordisk; For the treatment of congenital factor XIII (FXIII) A-subunit deficiency, Approved December of 2013
Farxiga (dapagliflozin); Bristol-Myers Squibb; For the treatment of type II diabetes, January of 2014
Myalept (metreleptin for injection); Bristol-Myers Squibb; For the treatment of congenital or acquired generalized lipodystrophy, Approved February of 2014
Northera (droxidopa); Chelsea Therapeutics; For the treatment of neurogenic orthostatic hypotension, Approved February 2014
Tivorbex (indomethacin); Iroko Pharmaceuticals; For the treatment of acute pain, Approved February of 2014
Vimizim (elosulfase alfa); BioMarin; For the treatment of Mucopolysaccharidosis type IVA, Approved February 2014
Imbruvica (ibrutinib); Pharmacyclics; For the treatment of chronic lymphocytic leukemia, Approved February 2014
Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014
코멘트 0|조회 1,238
인쇄| 최희영
-
레닌-안지오텐신계(RAS) 작용 의약품 관련 안전성 서한 2014-07-03 13:32 - 돔페리돈 함유 제제 관련 안전성서한 2014-07-03 13:25
- 최신약물정보 (FDA 승인 약물 2013.12-2014.2)
- 초산시프로테론,에티닐에스트라디올 복합제 안전성서한 배포 2014-03-18 09:16
- 치오콜치코시드 함유제제 안전성서한 배포 2014-03-18 09:16